retatrutide clinical trial data Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 conducted in the USA Phase III retatrutide study demonstrates

The strength of the TRIUMPH-1 data 28.3% weight loss at 80 weeks, 45.3% achieving bariatric-surgery-level outcomes gives Eli Lilly a compelling submission package

Some products marketed as bacteriostatic water don't meet pharmaceutical standards

[26] [27] They also act on appetite centres in the brain, particularly the hypothalamus, to reduce hunger signals and increase satiety

Issue Section License Copyright (c) 2025 Canadian Diabetes & Endocrinology Today This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License

It is labeled weight-neutral

Avoid repeated freeze-thaw cycles to preserve peptide integrity